Abstract
The term “familial male breast cancer” is often misleading, because in the breast cancer families reported in the literature, the vast majority of the patients were women and only a few were men. In this report, we present the rare case of a strictly defined familial male breast cancer (MBC) in which exclusively men were diagnosed with breast cancer. Three of four brothers developed the disease between the age of 46 and 64 years within a period of 21 years whereas all female relatives remained unaffected. The three affected men did not show the typical known clinical and genetic risk factors for MBC. An X-linked recessive inheritance may be possible in these cases. One way to potentially improve the identification of the causes of MBC could be a through a strictly studying families in which the male members were exclusively diagnosed with this malignancy. This approach emphasizes familial MBC as a distinct entity and not only as a variant of female breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367:595–604
Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10:471–479
Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122
Lanitis S, Rice AJ, Vaughan A et al (2008) Diagnosis and management of male breast cancer. World J Surg 32:2471–2476
Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314
Couch FJ, Farid LM, DeShano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123–125
Evans DG, Bulman M, Young K et al (2001) High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer 1:131–133
Evans DG, Bulman M, Young K et al (2008) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7:113–117
Miolo G, Puppa LD, Santarosa M et al (2006) Phenotypic features, genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer 6:156
Tournier I, Paillerets BB, Sobol H et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64:8143–8147
Demeter JG, Waterman NG, Verdi GD (1990) Familial male breast carcinoma. Cancer 65:2342–2343
Everson RB, Li FP, Fraumeni JF Jr et al (1976) Familial male breast cancer. Lancet 1:9–12
Hauser AR, Lerner IJ, King RA (1992) Familial male breast cancer. Am J Med Genet 44:839–840
Jones C, Oliver DJ, Van Merwyk AJ (1996) Familial male breast cancer. Med J Aust 164:640
Schwartz RM, Newell RB Jr, Hauch JF, Fairweather WH (1980) A study of familial male breast carcinoma and a second report. Cancer 46:2697–2701
Sodha N, Wilson C, Bullock SL et al (2004) Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215:187–189
Edge S, Byrd D, Compton C et al (2009) AJCC cancer staging manual. Springer, New York
Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors. Wiley-Blackwell, Oxford
Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158
Zanna I, Rizzolo P, Sera F et al (2010) The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet 18:856–858
Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410–414
Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108:477–478
Offit K, Pierce H, Kirchhoff T et al (2003) Frequency of CHEK2*1100delC in New York breast cancer cases, controls. BMC Med Genet 4:1
Ohayon T, Gal I, Baruch RG et al (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108:479–480
Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108:475–476
Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167
Sauty de Chalon A, Teo Z, Park DJ et al (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121:253–255
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4:174–191
Eden JA (2010) Breast cancer, stem cells and sex hormones Part 1. The impact of fetal life and infancy. Maturitas 67:117–120
Ruder EH, Dorgan JF, Kranz S et al (2008) Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer 8:334–342
Acknowledgments
The authors want to thank Dr. P. Schnell for providing clinical information concerning the three MBC patients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Güth, U., Müller, D., Huang, D.J. et al. Strictly defined familial male breast cancer. Familial Cancer 10, 73–77 (2011). https://doi.org/10.1007/s10689-010-9400-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-010-9400-3